Related references
Note: Only part of the references are listed.Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations
Tamara Maes et al.
PLOS ONE (2020)
First-in-Human Phase I Study of ladademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia
Olga Salamero et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Dopaminergic gene methylation is associated with cognitive performance in a childhood monozygotic twin study
Candace R. Lewis et al.
EPIGENETICS (2019)
Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable in vivo pharmacokinetics and pharmacodynamics studies of KDM1A inhibitors
Cristina Mascaro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
Cristina Mascaro et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2019)
Recapitulation and Reversal of Schizophrenia-Related Phenotypes in Setd1a-Deficient Mice
Jun Mukai et al.
NEURON (2019)
A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis
Kristen Pettit et al.
BLOOD (2019)
T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice
Satoru Matsuda et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Histone H3 lysine K4 methylation and its role in learning and memory
Bridget E. Collins et al.
EPIGENETICS & CHROMATIN (2019)
Aging in the Brain: New Roles of Epigenetics in Cognitive Decline
Jolie D. Barter et al.
NEUROSCIENTIST (2018)
The FAD-directed LSD1 specific inhibitor, INCB059872, is a promising epigenetic agent for AML therapy by inducing differentiation of leukemic stem/ progenitor cells
Antony Chadderton et al.
CANCER RESEARCH (2018)
The Contribution and Therapeutic Potential of Epigenetic Modifications in Alzheimer's Disease
Ian C. Wood
FRONTIERS IN NEUROSCIENCE (2018)
1832PDPhase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
A Hollebecque et al.
ANNALS OF ONCOLOGY (2018)
Epigenetic mechanisms during ageing and neurogenesis as novel therapeutic avenues in human brain disorders
Raul Delgado-Morales et al.
CLINICAL EPIGENETICS (2017)
KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease
Tamara Maes et al.
EPIGENOMICS (2015)
Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation
A. Spruessel et al.
LEUKEMIA (2012)
Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1
Shireen Saleque et al.
MOLECULAR CELL (2007)
Histone demethylation mediated by the nuclear arnine oxidase homolog LSD1
YJ Shi et al.
CELL (2004)
Share Paper
